OPKO Health (OPK), just signed a worldwide partnership deal with Pfizer, receives $295 million

By |2017-04-25T18:03:50+00:00December 28th, 2014|Pharma News|

Since its lows in mid-October, biotech stocks have sparkled, particularly the Big four – Amgen (AMGN), Biogen Idec (BIIB), Celgene (CELG), and Gilead (GILD) – which have demonstrated sustainable growth pathways. With the market’s renewed volatility in recent days, they have pulled back some, which only made them much more reasonably priced. But the more [...]

Comments Off on OPKO Health (OPK), just signed a worldwide partnership deal with Pfizer, receives $295 million

Pharma’s top 10 M&A deals of 2014’s first half

By |2014-12-09T17:13:42+00:00December 9th, 2014|Pharma News|

Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of the year; we will round out the entire year's activity in another report early next year. The top 10 deals [...]

Comments Off on Pharma’s top 10 M&A deals of 2014’s first half
Go to Top